Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Hiroaki Nagano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7074-3315; OpenAlex author ID A5026143596, A5083677685, A5090141439. Sources: OpenAlex.

Their work

Papers
62 (first author 6, last author 27)
Trials
0
Grants
0
Labs led
2
Collaborators
196
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 8 papers · 2014: 5 papers · 2015: 8 papers · 2016: 5 papers · 2017: 4 papers · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 7 papers · 2026: 4 papers

Papers 50 of 62

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Last author DOI 10.1002/ags3.70090↗
  2. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  3. Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy. Last author DOI 10.1016/j.suronc.2025.102333↗
  4. Immature Peritumoral Tertiary Lymphoid Structures Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After NAC. Last author DOI 10.21873/anticanres.18061↗
  5. Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003). Last author DOI 10.1002/cam4.70647↗
  6. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Last author DOI 10.1007/s00535-024-02186-9↗
  7. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Last author DOI 10.1007/s00535-025-02215-1↗
  8. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  9. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. Last author DOI 10.1111/cas.70087↗
  10. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  11. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Co-author DOI 10.1371/journal.pone.0325667↗
  12. Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). Last author DOI 10.1097/mpa.0000000000002323↗
  13. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-24-0226↗
  14. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. Last author DOI 10.3390/cancers16142522↗
  15. Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study. Last author DOI 10.21873/invivo.13380↗
  16. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  17. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000527342↗
  18. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  19. Hepatic artery resection and reconstruction using the right gastroepiploic artery during pancreaticoduodenectomy in advanced pancreatic cancer. Last author DOI 10.1007/s00423-021-02120-0↗
  20. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Last author DOI 10.1097/mpa.0000000000001772↗
  21. Adding Delayed Phase Images to Dual-Phase Contrast-Enhanced CT Increases Sensitivity for Small Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.20.25430↗
  22. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Last author DOI 10.3892/ol.2020.12291↗
  23. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Co-author DOI 10.1007/s00280-019-04005-y↗
  24. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.009↗
  25. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  26. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancre… Co-author DOI 10.1245/s10434-019-07735-8↗
  27. [Five Cases of Ten-Year Survival after Surgical Treatment of Pancreatic Cancer in Yamaguchi Prefecture]. Last author PMID 32156955↗
  28. Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Last author DOI 10.1080/14737140.2018.1531707↗
  29. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
  30. c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. Co-author DOI 10.3892/ol.2018.8793↗
  31. Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection. Last author DOI 10.1097/mcg.0000000000000551↗
  32. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Last author DOI 10.1097/mpa.0000000000000880↗
  33. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Last author DOI 10.1186/s13046-017-0509-1↗
  34. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes. Co-author DOI 10.1371/journal.pone.0184901↗
  35. Serum Metabolite Profiling for the Detection of Pancreatic Cancer: Results of a Large Independent Validation Study. Co-author DOI 10.1097/mpa.0000000000000680↗
  36. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Last author DOI 10.1111/cas.13061↗
  37. A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. First author DOI 10.3892/ijo.2015.3258↗
  38. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Last author DOI 10.3892/ol.2015.4057↗
  39. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy]. Last author PMID 28133195↗
  40. Implications of peritoneal lavage cytology in resectable left-sided pancreatic cancer. Last author DOI 10.1007/s00595-014-0964-7↗
  41. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Last author DOI 10.1093/jjco/hyu224↗
  42. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000205↗
  43. Susceptibility of pancreatic cancer stem cells to reprogramming. Co-author DOI 10.1111/cas.12734↗
  44. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells. Co-author DOI 10.3892/ijo.2014.2717↗
  45. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. First author DOI 10.3892/mco.2015.490↗
  46. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. First author DOI 10.3892/ol.2015.3667↗
  47. [Three Resected Cases of Metachronous Pancreatic Cancer Successfully Treated with Repeated Pancreatectomy]. Co-author PMID 26805359↗
  48. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  49. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. First author DOI 10.1007/s00280-013-2357-9↗
  50. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Co-author DOI 10.1038/bjc.2014.454↗

Closest collaborators

The 25 strongest of 196 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroto Matsui Matsui · 19 shared papers, 2016–2026 · strength 2.64
  2. Yoshitaro Shindo · 17 shared papers, 2016–2026 · strength 2.30
  3. Masao Nakajima · 9 shared papers, 2017–2026 · strength 1.67
  4. Tatsuya Ioka · 8 shared papers, 2021–2026 · strength 1.60
  5. Hidetoshi Eguchi · 32 shared papers, 2011–2021 · strength 1.47
  6. Yuichiro Doki · 28 shared papers, 2011–2020 · strength 1.23
  7. Ryouichi Tsunedomi · 7 shared papers, 2016–2026 · strength 1.21
  8. Junji Furuse · 6 shared papers, 2022–2025 · strength 0.98
  9. Makoto Ueno · 5 shared papers, 2022–2025 · strength 0.86
  10. Hidenori Takahashi · 6 shared papers, 2011–2026 · strength 0.83
  11. Nobuaki Suzuki · 8 shared papers, 2016–2023 · strength 0.74
  12. Hirofumi Akita · 12 shared papers, 2011–2025 · strength 0.74
  13. Yoshito Tomimaru · 15 shared papers, 2013–2020 · strength 0.67
  14. Chigusa Morizane · 4 shared papers, 2022–2026 · strength 0.66
  15. Masafumi Ikeda · 4 shared papers, 2022–2025 · strength 0.63
  16. Naohiro Okano · 4 shared papers, 2022–2025 · strength 0.63
  17. Akinori Asagi · 4 shared papers, 2022–2025 · strength 0.56
  18. Takeshi Terashima · 3 shared papers, 2025–2026 · strength 0.56
  19. Hiroshi Ohyama · 3 shared papers, 2025–2026 · strength 0.56
  20. Nana Kimura · 3 shared papers, 2025 · strength 0.55
  21. Shigeru Marubashi · 13 shared papers, 2011–2018 · strength 0.53
  22. Hiroshi Imaoka · 3 shared papers, 2025 · strength 0.52
  23. Satoshi Matsukuma · 6 shared papers, 2016–2021 · strength 0.50
  24. Yusaku Watanabe · 3 shared papers, 2016–2026 · strength 0.49
  25. Taro Takami · 3 shared papers, 2022–2025 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.